Alisertib - Takeda Oncology

Drug Profile

Alisertib - Takeda Oncology

Alternative Names: Alsertib; MLN-8237

Latest Information Update: 18 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Fox Chase Cancer Center; Massachusetts General Hospital; Mayo Clinic; Millennium; National Cancer Institute (USA); Northwestern University; Ohio State University Comprehensive Cancer Center; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine; Weill Cornell Medical College; Yale University School of Medicine
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Benzazepines; Benzoic acids; Fluorobenzenes; Phenyl ethers; Pyrimidines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; B cell lymphoma; Brain cancer; Breast cancer; Burkitt's lymphoma; Cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Gynaecological cancer; Head and neck cancer; Lymphoma; Mesothelioma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peripheral T-cell lymphoma; Prostate cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 14 Jun 2018 Safety and efficacy data from a phase I trial in Non-Hodgkin's lymphoma presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 08 May 2018 Takeda completes a phase III trial in Peripheral T cell lymphoma (Refractory metastatic disease, Second-line therapy or greater) in USA, Australia, Belarus, Brazil, Chile, Egypt, France, Israel, Mexico, New Zealand, Peru, Poland, Puerto Rico, Romania, Russia, Slovakia, Turkey, Canada, Sweden, Czech Republic, Portugal, Germany, Hungary, Austria, Spain, Denmark, Netherlands, Bulgaria, Italy, Belgium and the United Kingdom (NCT01482962) (EudraCT2011-003545-18)
  • 03 May 2018 Millennium Pharmaceuticals terminates a phase II trial due to slow patient enrolment in B-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT01812005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top